Vicki Moore, PhD

Contributing Writer https://www.hematologyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

General Hematology

Prognostic Model for Patients With Systemic Immunoglobulin Light-Chain Amyloidosis and Renal Involvement

Vicki Moore, PhD

August 13, 2019

Researchers identified 3 prognostic factors predictive of all-cause mortality in multivariate analyses.

Each of 3 reduced intensity conditioning regimens yielded similar outcomes in patients with MM.

Lymphoma

Rituximab With or Without Lenalidomide in First-Line Treatment of Follicular Lymphoma

Vicki Moore, PhD

August 12, 2019

Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.

Lymphoma

Follow-Up S0816 Trial Results: PET-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma

Vicki Moore, PhD

August 9, 2019

Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.

A team of doctors are meeting and consulting their tablets.

Bleeding Disorders

Efficacy Comparison of Emicizumab and Factor VIII Prophylaxis Treatments in Hemophilia A Without Inhibitors

Vicki Moore, PhD

August 8, 2019

Researchers conducted a meta-analysis of 4 studies examining prophylaxis with factor VIII or emicizumab for hemophilia A without inhibitors.

Venetoclax and ibrutinib are therapeutic agents for CLL.

Leukemia

Improved Survival Outcomes With Ibrutinib Plus Rituximab in Chronic Lymphocytic Leukemia

Vicki Moore, PhD

August 7, 2019

Patients who received ibrutinib and rituximab had a 3-year PFS rate of 89.4%, compared with 72.9% in patients receiving chemoimmunotherapy.

Researchers assessed incidence of recurrent thromboembolism and major bleeding in patients with cancer and incidental pulmonary embolism.

Thrombotic Disorders

Increased Risk for Venous Thromboembolism in Patients Receiving Anticoagulant Therapy for Pulmonary Embolism

Vicki Moore, PhD

July 23, 2019

Researchers assessed incidence of recurrent thromboembolism and major bleeding in patients with cancer and incidental pulmonary embolism.

A scientist looks at trial results on her computer.

Leukemia

Prognostic Model for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Vicki Moore, PhD

July 22, 2019

Researchers sought to develop a model that can be used to identify patients receiving targeted therapy for CLL who are at high risk for poor outcomes.